Tocilizumab drug interactions | Litt's Drug Eruption and Reaction Database

(2019): Isaacs JD+, Rheumatol Adv Pract 3(1), eCollection6% (serious) (± combination therapy with conventional synthetic disease-modifying antirheumatic drugs (DMARDs))

(2018): Nakaoka Y+, Ann Rheum Dis 77(3), 348 (serious / 1 case)

(2017): Caporali R+, Clin Exp Rheumatol 35(6), 91929%

(2017): Notario Ferreira I+, Reumatol Clin 13(2), 78

(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 600

(2016): Albattal BM, Ann Saudi Med 36(3), 19011%

(2016): Regent A+, J Rheumatol 43(8), 1547

(2016): Yokota S+, Ann Rheum Dis 75(9), 165469%

(2015): Tarkiainen M+, Rheumatology (Oxford) 54(7), 1170

(2014): Machado-Alba JE+, Rev Panam Salud Publica 36(6), 396

(2013): Gabay C+, Lancet 381(9877), 154112%

(2012): Imagawa T+, Mod Rheumatol 22(1), 109

(2008): Genovese MC+, Arthritis Rheum 58(10), 29687%

Allergic reactions

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Cancer

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

Death

(2019): Isaacs JD+, Rheumatol Adv Pract 3(1), eCollection (1 case) (± combination therapy with conventional synthetic disease-modifying antirheumatic drugs (DMARDs))

(2018): Ogata A+, Mod Rheumatol 28(1), 76 (1 case)

(2017): Ishiguro N+, Mod Rheumatol 27(2), 2171%

(2016): Khanna D+, Lancet 387(10038), 2630 (1 case)

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2012): Kawashiri SY+, Rheumatol Int 32(12), 4023

Infection

(2019): Giles JT+, Arthritis Rheumatol Aug, Epub ahead of print

(2018): Iannone F+, Clin Rheumatol 37(2), 315

(2018): Ogata A+, Mod Rheumatol 28(1), 76

(2017): Ishiguro N+, Mod Rheumatol 27(2), 21712%

(2017): Jones G+, J Rheumatol 44(2), 142

(2017): Machado SH+, Expert Opin Drug Saf 16(4), 493 [REVIEW]

(2016): Khanna D+, Lancet 387(10038), 263016%

(2016): Kivitz A+, Rheumatol Ther 3(2), 2914% (serious)

(2016): Teitsma XM+, Arthritis Res Ther 18(1), 211 [REVIEW] (skin and respiratory)

(2016): Yokota S+, Ann Rheum Dis 75(9), 165441%

(2015): Brunner HI+, Ann Rheum Dis 74(6), 1110

(2015): Horneff G, Expert Opin Drug Saf 14(7), 1111 [REVIEW]

(2015): McLaughlin M+, Expert Opin Drug Saf 14(3), 429 [REVIEW]

(2015): Wang G+, Int J Gen Med 8, 187

(2014): Dhillon S, BioDrugs 28(1), 75 [REVIEW]

(2014): Nakashima Y+, Drug Des Devel Ther 8, 913

(2014): Navarro G+, Semin Arthritis Rheum 43(4), 458

(2014): Stoll ML+, Pediatr Rheumatol Online J 12, 13

(2014): Yokota S+, J Rheumatol 41(4), 759

(2013): Dougados M+, Ann Rheum Dis 72(1), 43

(2013): Milin M+, Joint Bone Spine 80(2), 221

(2013): Nguyen MT+, BMJ Case Rep 2013 (3 cases)

(2013): Weinblatt ME+, Arthritis Care Res (Hoboken) 65(3), 362

(2012): Bykerk VP+, Ann Rheum Dis 71(12), 1950

(2012): De Benedetti F+, N Engl J Med 367(25), 2385

(2012): Yazici Y+, Ann Rheum Dis 71(2), 198

(2011): Bannwarth B+, Expert Opin Drug Saf 10(1), 123 [REVIEW]

(2011): Burmester GR+, Ann Rheum Dis 70(5), 7553%

(2011): Inayama M+, Kansenshogaku Zasshi (Japanese) 85(5), 523

(2011): Koike T+, Ann Rheum Dis 70(12), 2148

(2010): Hirabayashi Y+, Rheumatol Int 30(8), 1041

(2010): Jones G, Expert Rev Clin Immunol 6 (2), 189

(2010): Nishimoto N+, Mod Rheumatol 20(3), 222

(2010): Tanaka T+, Expert Rev Clin Immunol 6(6), 843

(2008): Emery P+, Ann Rheum Dis 67(11), 1516

(2008): Genovese MC+, Arthritis Rheum 58(10), 29687%

(2008): Plushner SL, Ann Pharmacother 42(11), 1660 [REVIEW]

(2008): Smolen JS+, Lancet 371, 987

(2007): Nishimoto N+, Ann Rheum Dis 66(9), 1162

(2006): Ding C+, Rev Recent Clin Trials 1(3), 193 [REVIEW]

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tocilizumab in the treatment of juvenile idiopathic arthritis in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)